Bushra firdous Shaik

Dr. Bushra firdous Shaik

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
RNRoopa Naik
Roopa Naik
SASreekant Avula
Sreekant Avula
SPSUJITH KUMAR PALLETI
SUJITH KUMAR PALLETI
JGJyotsna Gummadi
Jyotsna Gummadi
RRRajarajeshwari Ramachandran
Rajarajeshwari Ramachandran
ABAtul Bali
Atul Bali
Severe Acute Respiratory Syndrome Coronavirus - 2 (SARS-CoV-2), later renamed Coronavirus Disease 2019 (COVID-19) was first identified in Wuhan, China, in early December 2019. Initially, the China office of the World Health Organization was informed of numerous cases of pneumonia of unidentified etiology in Wuhan, Hubei Province on December 31, 2019. This would subsequently result in a global pandemic with over 76 million confirmed cases of COVID-19 and 6.9 million deaths reported to the WHO. We have analyzed most of the data published since the beginning of the pandemic to compile this comprehensive review of SARS-CoV-2. We look at the core ideas, such as the etiology, epidemiology, pathogenesis, clinical symptoms, diagnostics, histopathologic findings, consequences, therapies, and vaccines. We have also included the long-term effects and myths associated with some therapeutics of COVID-19. This study comprehensively assesses of the SARS-CoV-2 virology, vaccines, medicines, and significant variants identified during the pandemic. Our review article is intended to provide medical practitioners with a better understanding of the fundamental sciences, clinical treatment, and prevention of COVID-19. As of June 2023, this paper contains the most recent data made accessible.

5 January 2026 in Journal For International Medical Graduates
Verified
Journal Article
Open access
PDF file
BSBushra firdous Shaik
Bushra firdous Shaik
EEExcel Ernest-Okonofua
Excel Ernest-Okonofua
OMOmar Ahmed Mohammed Sami Mahroq
Omar Ahmed Mohammed Sami Mahroq
SGShakirat Oyindolapo Ganiyu
Shakirat Oyindolapo Ganiyu
RNRithish Nimmagadda
Rithish Nimmagadda
MNMarcellina Nwosu
Marcellina Nwosu
Sickle cell disease (SCD) is a chronic, inherited blood disorder marked by the presence of abnormal hemoglobin, which causes red blood cells to assume a rigid, sickle-like shape. These distorted cells contribute to hemolysis, impaired blood flow, and recurrent vaso-occlusive crises (VOCs), the hallmark and most debilitating complication of the disease. Beyond acute pain episodes, Sickle cell disease leads to progressive organ damage and reduced life expectancy, placing a substantial burden on patients and healthcare systems worldwide. While supportive care has long been the cornerstone of management, the emergence of targeted therapies offers new hope. Crizanlizumab, a humanized monoclonal antibody directed against P-selectin, disrupts the cellular adhesion processes that drive vaso-occlusive crises. This review highlights the pathophysiology of Sickle cell disease, details the mechanism of action of crizanlizumab, and evaluates clinical trial evidence regarding its efficacy, safety, and therapeutic potential. Collectively, the findings underscore crizanlizumab’s promise as a transformative therapy that can reduce VOC frequency and improve quality of life for individuals living with SCD.